Oculis’ (OCS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oculis (NASDAQ:OCS) in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a $26.00 target price on the stock.

A number of other brokerages also recently commented on OCS. Stifel Nicolaus lowered their price objective on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, June 1st. JPMorgan Chase & Co. cut their target price on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Wall Street Zen downgraded shares of Oculis from a “sell” rating to a “strong sell” rating in a report on Sunday, July 12th. Robert W. Baird lowered their price target on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research report on Monday, June 1st. Finally, Guggenheim dropped their price objective on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oculis presently has an average rating of “Moderate Buy” and a consensus target price of $38.33.

Oculis Stock Performance

Shares of OCS stock opened at $12.68 on Wednesday. The company has a market cap of $735.19 million, a P/E ratio of -7.29 and a beta of 0.51. The business has a 50 day moving average of $12.17 and a two-hundred day moving average of $22.31. Oculis has a 52 week low of $10.52 and a 52 week high of $34.47. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 45.58% and a negative net margin of 6,777.18%. As a group, analysts anticipate that Oculis will post -2.22 EPS for the current year.

Institutional Trading of Oculis

Several hedge funds have recently added to or reduced their stakes in OCS. China Universal Asset Management Co. Ltd. boosted its position in Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the period. Koshinski Asset Management Inc. acquired a new position in shares of Oculis during the first quarter valued at $238,000. Millennium Management LLC bought a new stake in shares of Oculis during the fourth quarter valued at about $312,000. Himension Capital Singapore PTE. LTD. bought a new stake in shares of Oculis during the first quarter valued at about $503,000. Finally, Marshall Wace LLP acquired a new stake in Oculis in the second quarter worth about $393,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.